Heidelberg Pharma is a biopharmaceutical company focused on developing cancer therapies using ADC (Antibody Drug Conjugate) technologies.

Heidelberg Pharma

Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. 

Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. 
Former clinical assets MESUPRON® and REDECTANE® have been partnered.

Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

dievini Hopp Biotech Holding

Huadong Medicine

Huadong Investment

Heidelberg Pharma AG

📢We are happy to attend the LSX World Congress USA in
Boston on September 11th and 12th!  📢
  
Learn more about Heidelberg Pharma AG´s unique ADC technologies, which have the potential to transform the lives of cancer patients. Find a strategic partner to advance your company and discuss with Artjom Wischnjow business opportunities. Join him via the online partnering system https://t1p.de/kb1qf

#ADC #ATAC #CancerResearch

📢We are happy to attend ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit! See you in Boston in early September! 📢 
  
Learn more about Heidelberg Pharma AG´s unique ADC-technologies, which have the potential to transform the lives of cancer patients. Join Artjom Wischnjow to access strategic knowledge and form new partnerships.

#ADC #ATAC #CancerResearch

🏅 Auch sportlich Spitzenreiter: Bei der bundesweiten Aktion STADTRADELN belegte das Team „Dynamo Heidelberg Pharma AG“ den 10. Platz von insgesamt 38 Ladenburger Teams.  

Herzlichen Glückwunsch!

🚲 Gemeinsam haben die Kolleginnen und Kollegen rund 3.500 Kilometer auf dem Rad zurückgelegt und sind 187 Mal lieber in den Sattel gestiegen, anstatt sich hinter das Lenkrad zu klemmen und konnten so rund 600 kg/Co2 -Ausstoß vermeiden.  

Starke Leistung!

📌 STADTRADELN findet bundesweit einmal im Jahr statt. Jede Gemeinde legt ihren eigenen Aktionszeitraum fest. Infos rund um die Fahrradaktion, die mehr Bewusstsein für umweltfreundliche Verkehrsmittel schaffen möchte, gibt es hier: https://t1p.de/j9jg

🌟 Unveiling the Power of Amanitin in Cancer Therapy! 🌟
 
Our lead programs at Heidelberg Pharma AG are harnessing the potential of #amanitin, a groundbreaking new payload derived from the deadly green death-cap mushroom. This unique bicyclic octopeptide stands out from other payloads due to its exceptional stability and hydrophilicity, offering distinct advantages in drug formulation and manufacturing.
 
Watch the clip to learn more about how we're leveraging these unique properties to pioneer the next generation of cancer treatments. For a deeper dive, check out the full webinar here: https://lnkd.in/eVJygzyn 
 
#ADCs #ATAC #Oncology #HeidelbergPharma

🔎 Discover the power behind our platform! 🔍 
 
In our recent R&D webinar, we discussed how our proprietary platform, secured by multiple IP families, is revolutionizing cancer therapy. To the best of our knowledge, Heidelberg Pharma AG is the only company worldwide developing amanitin as a novel payload for antibody-drug conjugates (#ADCs). Our robust IP strategy ensures a strong monopoly in this space, keeping competitors at bay. We've also successfully established a reliable supply chain for the GMP manufacturing of amanitin and amanitin-based ADCs.
 
📺 Watch the full recording to learn more about how our cutting-edge approach is setting new standards in cancer treatment: https://lnkd.in/eVJygzyn
 
#ADC #ATAC #CancerResearch

🌟 Unlocking New Potential in Cancer Therapy! 🌟
 
"The efficacy against dormant tumor cells will probably lead to longer progression-free survival for these patients. We have seen efficacy in very low target-expressing tumor cells, which we believe can lead to deeper responses and higher response rates. The mode of action is radically new to all patients, allowing us to overcome resistance."
 
📺 Watch our R&D webinar to learn more about how the team at Heidelberg Pharma AG is achieving deeper responses and overcoming resistance with our innovative approach: https://lnkd.in/eVJygzyn
 
#ADCs #ATAC #CancerResearch

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.

XETRA:HPHA

Heidelberg Pharma

Last Close

2.52

30/08 15:36

Market Cap

118.37M

Beta: −0.26

Volume Today

15.82K

Avg: 2.55K

PE Ratio

−6.82

PFCF: −4.31